Literature DB >> 11166110

The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats.

H Kittner1, U Krügel, P Illes.   

Abstract

Repeated administration of amphetamine-like psychostimulants produce a progressive and long-lasting hypersensitivity to their behavioural effects known as behavioural sensitization. Previous studies have shown that administration of the purinergic P2 receptor agonist 2-methylthio ATP into the nucleus accumbens of rats raises the extracellular level of dopamine accompanied with enhanced locomotion in a similar manner. Furthermore, the quantitative EEG after application of 2-methylthio ATP or amphetamine was characterized by an elevation of the alpha1-power. However, purinergic P2 receptor antagonists decreased the basal level of dopamine in the NAc and in addition prevented the effects of 2-methylthio ATP. The purpose of the present study was to investigate, whether endogenous ATP acting via purinergic P2 receptors is involved in the process of amphetamine-induced sensitization. Rats were treated systemically for five successive days with d-amphetamine (1.5 mg/kg) and tested in an open field with respect to their locomotor response. The enhanced locomotor activity after the first injection of amphetamine was diminished by the previous intracerebroventricular application of the purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid (PPADS; 0.6 nmol) (P<0.05). The challenge with a lower dose of amphetamine (0.75 mg/kg) produced an increased locomotion in comparison to the response after the first amphetamine application indicating the expression of a behavioural sensitization. Pretreatment with PPADS prior to each amphetamine administration prevented the increase of locomotor activity after the challenge with amphetamine (P<0.05). In summary, the present study demonstrates that PPADS blocks both the acute locomotor effects of amphetamine and the development of behavioural sensitization to the psychostimulant. We suggest that the activation of purinergic P2 receptors by endogenous ATP is necessary for the expression of these effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166110     DOI: 10.1016/s0306-4522(00)00555-8

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  8 in total

Review 1.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

Review 2.  P2 receptors and neuronal injury.

Authors:  Heike Franke; Ute Krügel; Peter Illes
Journal:  Pflugers Arch       Date:  2006-04-28       Impact factor: 3.657

3.  Purinergic Antagonism Prevents Mitochondrial Dysfunction and Behavioral Deficits Associated with Dopaminergic Toxicity Induced by 6-OHDA in Rats.

Authors:  Saket Kumar; Akanksha Mishra; Sairam Krishnamurthy
Journal:  Neurochem Res       Date:  2017-08-24       Impact factor: 3.996

4.  Synthetic cathinone MDPV enhances reward function through purinergic P2X7 receptor-dependent pathway and increases P2X7 gene expression in nucleus accumbens.

Authors:  Taylor A Gentile; Steven J Simmons; Christopher S Tallarida; Shu Su; Slava Rom; Mia N Watson; Allen B Reitz; Raghava Potula; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2019-01-31       Impact factor: 4.492

5.  Electroconvulsive therapy: a novel hypothesis for the involvement of purinergic signalling.

Authors:  Ahmed-Ramadan Sadek; Gillian E Knight; Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2011-06-22       Impact factor: 3.765

Review 6.  Modulation of excitatory neurotransmission by neuronal/glial signalling molecules: interplay between purinergic and glutamatergic systems.

Authors:  László Köles; Erzsébet Kató; Adrienn Hanuska; Zoltán S Zádori; Mahmoud Al-Khrasani; Tibor Zelles; Patrizia Rubini; Peter Illes
Journal:  Purinergic Signal       Date:  2015-11-06       Impact factor: 3.765

7.  Enhanced P2Y1 receptor expression in the brain after sensitisation with d-amphetamine.

Authors:  Heike Franke; Holger Kittner; Jens Grosche; Peter Illes
Journal:  Psychopharmacology (Berl)       Date:  2003-03-22       Impact factor: 4.530

8.  P2 receptors are involved in the mediation of motivation-related behavior.

Authors:  Ute Krügel; Oliver Spies; Ralf Regenthal; Peter Illes; Holger Kittner
Journal:  Purinergic Signal       Date:  2004-12       Impact factor: 3.765

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.